NKTX running out of steamAs evident, NKTX is firmly away from the nice bull channel it had found itself in, seems to be losing grip of support, and is in danger of falling into a pretty steep down channel. My short thesis is that the gravity of the situation is too much, and it will break. Stop are above Friday's high.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.66 USD
−108.79 M USD
0.00 USD
49.99 M
About Nkarta, Inc.
Sector
Industry
CEO
Paul J. Hastings
Website
Headquarters
South San Francisco
Founded
2005
FIGI
BBG00JXHS9G7
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.
Nkarta to 15$NASDAQ:NKTX
Looking like a technical reversal on the daily chart - MACD, TTM, and MACD look very resilient after a selloff.
Analysts set price targets at 15$, indicators seem to match up with this. Earnings in 17 days and mid-year treatment trials could be catalysts to move the price towards th
NKTX: A technical perspectiveNASDAQ:NKTX is a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. While highly speculative, the daily charts have presented a purchasing opportunity after a stock offering to raise capital.
MACD an
NKTX | Oversold Healthcare Play | LONGNkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific p
NKTX LONG SET UPNKTX LONG SET UP
Sector: Health Technology
Industry: Biotechnology
Employees: ---
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company was founded by Dario Campana in
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where NKTX is featured.

Mid-weight oncology stocks: The dark horses of cancer research
18 No. of Symbols
See all sparks
Related stocks
Frequently Asked Questions
The current price of NKTX is 1.81 USD — it has increased by 3.43% in the past 24 hours. Watch Nkarta, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Nkarta, Inc. stocks are traded under the ticker NKTX.
NKTX stock has risen by 17.53% compared to the previous week, the month change is a 11.73% rise, over the last year Nkarta, Inc. has showed a −76.94% decrease.
We've gathered analysts' opinions on Nkarta, Inc. future price: according to them, NKTX price has a max estimate of 18.00 USD and a min estimate of 8.00 USD. Watch NKTX chart and read a more detailed Nkarta, Inc. stock forecast: see what analysts think of Nkarta, Inc. and suggest that you do with its stocks.
NKTX reached its all-time high on Dec 24, 2020 with the price of 79.16 USD, and its all-time low was 1.28 USD and was reached on Oct 2, 2023. View more price dynamics on NKTX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
NKTX stock is 6.71% volatile and has beta coefficient of 1.06. Track Nkarta, Inc. stock price on the chart and check out the list of the most volatile stocks — is Nkarta, Inc. there?
Today Nkarta, Inc. has the market capitalization of 124.18 M, it has increased by 8.92% over the last week.
Yes, you can track Nkarta, Inc. financials in yearly and quarterly reports right on TradingView.
Nkarta, Inc. is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
NKTX earnings for the last quarter are −0.35 USD per share, whereas the estimation was −0.40 USD resulting in a 13.56% surprise. The estimated earnings for the next quarter are −0.43 USD per share. See more details about Nkarta, Inc. earnings.
Nkarta, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
NKTX net income for the last quarter is −25.93 M USD, while the quarter before that showed −28.34 M USD of net income which accounts for 8.50% change. Track more Nkarta, Inc. financial stats to get the full picture.
No, NKTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 18, 2025, the company has 157 employees. See our rating of the largest employees — is Nkarta, Inc. on this list?
Like other stocks, NKTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Nkarta, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Nkarta, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Nkarta, Inc. stock shows the sell signal. See more of Nkarta, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.